
THE INVESTMENT TRUST OF INDIA
RETAIL BROKING

ITI Muhurat Picks.
Samvat- 2083

DATE- 03/11/2026





Buy above 825

IHCL

SL 750 TGT 1050.

- The Indian Hotels Company Limited (IHCL) is one of India's leading hospitality companies and a part of the prestigious Tata Group. Established in 1902, the company operates a diversified portfolio of hospitality brands, including Taj, Vivanta, Ginger, SeleQtions, Gateway, and Tree of Life. With a strong presence across domestic and international markets, IHCL has built a reputation for premium hospitality, operational excellence, and customer-centric services.

- In FY25, IHCL reported consolidated revenue of ₹8,565 crore, registering a strong year-on-year growth of 23%. EBITDA increased by 28% to ₹3,000 crore, while Profit After Tax (PAT) stood at ₹1,908 crore, reflecting robust operating performance, improved margins, and healthy demand across its hospitality businesses.

- The company's growth has been supported by strong demand in the domestic tourism and business travel segments, higher room occupancy, improved average room rates, and growth in food and beverage services. Its diversified portfolio across luxury, upscale, and mid-scale hospitality segments provides multiple revenue streams and strengthens its market positioning.

- IHCL continued to expand its footprint during FY25, reaching a portfolio of approximately 380 hotels, including 74 new hotel signings and 26 hotel openings. Its asset-light expansion strategy, focus on premium hospitality, digital transformation, and expansion into emerging travel destinations position the company to benefit from India's growing tourism industry and rising demand for quality hospitality services.

- **Financial note:** FY25 reported PAT of ₹1,908 crore includes exceptional gains. PAT before exceptional items was ₹1,603 crore.

STOCK DATA

NSE code	INDHOTEL
CMP	₹ 822.50
Market Cap	₹ 1,17,077Cr
High / Low	₹ 831 / 565
Stock P/E	58.2
Dividend Yield	0.40%
ROE	15.4%



TradingView

Buy above 3,535

SL 3,170 TGT 4,700.

- BSE Limited is one of India's leading stock exchange operators and the world's oldest stock exchange, established in 1875. The company provides a platform for trading in equities, derivatives, currencies, debt instruments, and other financial products. Through its integrated market infrastructure, including the BSE StAR MF mutual fund platform and clearing and settlement services, BSE plays a significant role in India's capital markets.


- In FY25, BSE reported record consolidated revenue of approximately ₹3,236 crore, registering year-on-year growth of 103%. Consolidated net profit attributable to shareholders stood at approximately ₹1,326 crore, reflecting strong growth in trading activity, improved operating leverage, and higher revenue generation across its businesses. Operating EBITDA, including the contribution to the Core Settlement Guarantee Fund, reached approximately ₹1,499 crore, highlighting a significant improvement in operating performance.

- The company's growth was primarily driven by increased activity in the equity derivatives segment, which generated revenue of approximately ₹1,415 crore during FY25. Additionally, its BSE StAR MF platform recorded 66.3 crore transactions, representing 61% year-on-year growth and reinforcing its strong position in India's mutual fund distribution ecosystem.

- BSE continues to benefit from the expansion of India's investor base, increasing retail participation, growing derivatives activity, and the rising adoption of mutual fund investments. Its focus on technology, market infrastructure, product innovation, and operational efficiency positions the company to capitalise on the long-term growth potential of India's financial markets.

STOCK DATA

NSE code	BSE
CMP	₹ 3,490.00
Market Cap	₹ 1,42,352Cr
High / Low	₹ 4,447 / 2,377
Stock P/E	50.3
Dividend Yield	0.29%
ROE	46.0 %



TradingView

Buy above 910

SL 750 TGT 1,250.

- Sona BLW Precision Forgings Limited (Sona Comstar) is a leading Indian automotive technology company specialising in precision-engineered components and systems for electric and conventional vehicles. The company has a diversified global presence, supplying products such as differential assemblies, gears, motors, and driveline systems to leading automotive manufacturers. Its focus on advanced engineering, product innovation, and electric vehicle (EV) technologies positions it to benefit from the ongoing transformation of the global automotive industry.

- In FY25, Sona Comstar reported consolidated revenue from operations of approximately ₹3,555 crore, registering year-on-year growth of 12%. EBITDA stood at approximately ₹975 crore, with an EBITDA margin of 27.4%, while Profit After Tax (PAT) reached approximately ₹601 crore, reflecting 16% year-on-year growth. The company's performance was supported by growth in electric vehicle-related businesses, operational efficiency, and increasing demand for advanced automotive components.

- The company's electric vehicle business remained a key growth driver, with battery electric vehicle (BEV) revenue increasing by 38% year-on-year and contributing 36% of total revenue in FY25. Its diversified product portfolio, technological capabilities, and established relationships with global automotive manufacturers strengthen its competitive position in the evolving mobility ecosystem.

- Sona Comstar's growth strategy focuses on expanding its EV product portfolio, securing new customer programmes, developing advanced mobility solutions, and strengthening its global presence. As of March 2025, the company reported a record net order book of approximately ₹24,200 crore, with EV programmes accounting for 77% of the total. This provides visibility into potential future business growth, although actual execution will depend on customer demand, programme ramp-ups, and broader automotive industry conditions.

STOCK DATA

NSE code	SONACOMS
CMP	₹ 905.95
Market Cap	₹ 56,638Cr
High / Low	₹ 911/ 438
Stock P/E	70.20
Dividend Yield	0.38%
ROE	11.7%


Sona BLW Precision Forgings Ltd. · 1W · NSE O900.00 H911.25 L890.05 C905.95 +15.45 (+1.73%)
Vol 2.78M
EMA (20, close, 0, SMA, 5) 771.76
On the weekly chart, the stock continues to maintain its bullish structure, characterised by the formation of higher highs and higher lows, indicating sustained upward momentum.
The stock has witnessed a rebound from its 20 WEMA support, indicating buying interest at lower levels.
The formation of a strong bullish candle accompanied by higher-than-average trading volume indicates significant buying interest and possible accumulation in the stock.
INR
905.95
3d 8h
826.55
850.00
800.00
750.00
700.00
650.00
600.00
550.00
500.00
450.00
400.00
350.00
RSI (14, close) 71.47 71.59
80.00
60.00
40.00
2024
Mar
May
Jul
Sep
Nov
2025
Mar
May
Jul
Sep
Nov
2026
Mar
May
Jul
Sep
Nov
TradingView

Buy above 4,680

SL 4,320 TGT 5,700.

- **Torrent Pharmaceuticals Limited** is one of India's leading pharmaceutical companies and a part of the Torrent Group. The company has a strong presence in domestic and international pharmaceutical markets, with a diversified product portfolio across therapeutic segments such as cardiovascular, central nervous system, gastroenterology, and diabetes care. Its focus on branded formulations, research and development, and strong distribution capabilities has helped establish its position in the global pharmaceutical industry.

- In FY26, Torrent Pharmaceuticals reported consolidated revenue of approximately ₹13,980 crore, registering year-on-year growth of 21%. Operating EBITDA increased by 23% to ₹4,559 crore, with an EBITDA margin of approximately 33%, while Profit After Tax (PAT) stood at around ₹2,138 crore. In Q2 FY27, the company reported consolidated revenue of ₹4,979 crore, registering 51% year-on-year growth, while operating EBITDA increased by approximately 54% to ₹1,666 crore. However, PAT declined by 9.6% to ₹534 crore, primarily reflecting higher finance costs and depreciation following the consolidation of JB Pharma.

- The Indian pharmaceutical business remained a key growth driver, with domestic base business revenue increasing by 20% to ₹2,181 crore during Q2 FY27. International operations also recorded healthy growth, with US revenue increasing by 24% to ₹417 crore and Brazil revenue rising by 38% to ₹440 crore. The acquisition of JB Chemicals & Pharmaceuticals has further strengthened Torrent's product portfolio, market presence, and therapeutic reach, while providing opportunities for operational synergies and long-term business expansion.

- Torrent Pharmaceuticals continues to focus on strengthening its domestic market presence, expanding international operations, developing new formulations, and integrating its recently acquired JB Pharma business. Its established presence in chronic therapies, strong branded product portfolio, healthy operating margins, and expanding global footprint position the company to benefit from the long-term growth potential of the pharmaceutical industry.

STOCK DATA

NSE code	TORNTPHARM
CMP	₹ 4,595.00
Market Cap	₹ 1,74,779Cr
High / Low	₹ 5,250 / 3,533
Stock P/E	80.50
Dividend Yield	0.83%
ROE	27.4%



TradingView

Buy above 880

SL 790 TGT 1,150.

- **Indian Bank** is one of India's leading public sector banks, established in 1907 and headquartered in Chennai. The bank provides a wide range of banking and financial services, including retail banking, corporate banking, MSME financing, agricultural loans, and digital banking solutions. With an extensive branch network across India and an international presence, Indian Bank plays an important role in supporting financial inclusion, credit growth, and the country's economic development.

- In FY26, the bank continued to strengthen its financial performance, supported by healthy credit growth, improving asset quality, and operational efficiency. In Q2 FY27, Indian Bank reported standalone net profit of ₹3,462 crore, registering year-on-year growth of 14.71%. Net Interest Income (NII) increased by 17.83% to ₹7,719 crore, while operating profit grew by 46.58% to ₹7,090 crore. The bank's domestic Net Interest Margin (NIM) stood at 3.42%, reflecting a healthy core banking performance.

- The bank's total business increased by 14.22% year-on-year to approximately ₹15.96 lakh crore as of September 2026. Total advances grew by 16.39% to ₹7.22 lakh crore, while deposits increased by 12.50% to ₹8.74 lakh crore. Retail, Agriculture, and MSME (RAM) lending remained important growth drivers. Asset quality improved further, with Gross Non-Performing Assets (GNPA) declining to 1.61% from 2.60% a year earlier, while Net NPA (NNPA) stood at a low 0.14%.

- Indian Bank continues to focus on expanding its retail and MSME lending portfolio, strengthening digital banking infrastructure, improving operational efficiency, and maintaining disciplined asset quality. Its healthy credit growth, improving profitability, strong provision coverage ratio of 98.22%, and growing digital transaction base position the bank to benefit from increasing credit demand and India's expanding banking sector. However, investors should monitor interest rate movements, deposit mobilisation costs, credit growth, and potential changes in asset quality.

STOCK DATA

NSE code	INDIANB
CMP	₹ 865.25
Market Cap	₹ 1,16,546 Cr
High / Low	₹ 1,001 / 764
Stock P/E	8.82
Dividend Yield	2.11%
ROE	15.4%


Indian Bank · 1W · NSE O868.95 H874.15 L852.10 C865.25 −0.25 (−0.03%)
Vol 863.44K
EMA (50, close, 0, SMA, 5) 829.82
The stock has successfully held its 50 WEMA support and rebounded from this level, indicating buying interest and the potential continuation of the bullish trend.
On the weekly chart, the stock continues to maintain its bullish structure, characterised by the formation of higher lows, indicating sustained buying interest at lower levels.
The stock continues to respect its horizontal support level, indicating consistent buying interest at lower levels.
INR
1,000.00
900.00
865.25
3d 8h
800.00
765.45
700.00
600.00
500.00
400.00
300.00
200.00
100.00
RSI (14, close) 52.56 50.53
80.00
60.00
40.00
The RSI has broken above its falling trendline resistance and is gradually moving northward, indicating improving momentum and a potential strengthening of bullish sentiment.
2023
Jul
2024
Jul
2025
Jul
2026
Jul
TradingView

Disclaimer

This report has been prepared by ITI Securities Broking Limited (hereinafter referred to as ITISBL) to provide information about the company(ies) and/sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). ITISBL is a Stock Broker and Depository Participant registered with and regulated by Securities & Exchange Board of India. ITISBL and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group.

This report is for personal information of the selected recipient/s and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and ITISBL is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients.. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that ITISBL and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on the profitability of ITISBL which may include earnings from investment banking and other business.

ITISBL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, ITISBL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. ITISBL and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of ITISBL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition ITISBL has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt ITISBL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold ITISBL or any of its affiliates or employees responsible for any such misuse and further agrees to hold ITISBL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent ITISBL's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavour to update the information herein on reasonable basis, ITISBL and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent ITISBL and/or its affiliates from doing so. ITISBL or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ITISBL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This report is intended for distribution to investors. Recipients who are not investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents ITISBL and its associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ITISBL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. Subject Company may have been a client of ITISBL or its associates during twelve months preceding the date of distribution of the research report. ITISBL and/or its affiliates and/or Research analyst / or relative of research analyst or Employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, ITISBL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Neither the Research Analysts nor ITISBL have been engaged in market making activity for the companies mentioned in the report. ITISBL and/or its affiliates and/or Research analyst/ relative of research analyst have not any material conflict of interest at the time of publication of this report. There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of ITISBL research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

Disclosure of Interest Statement - Companies where there is interest

Analyst ownership of the stock: No

Served as an officer, director or employee: No

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ITISBL & its group companies to registration or licensing requirements within such jurisdictions.

ITI Securities Broking Limited
SEBI – Research Analyst REG. NO. : INH000001535
SEBI REG. NO: NSE&BSE: INZ000005835, CDSL-IN-DP-70-2015, AMFI Reg. No. ARN-12576,
CIN NO: U74120MH1994PLC077946
ITI House, 36, Dr. R. K. Shirodkar Road,
Parel, Mumbai - 400 012,
Boardline - (91) 22 69093600 Fax- 022 69093700

For queries, write to us at iti.research@itiorg.com